Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Envista Holdings CorpNVST · Entity 4007 | General Counsel | February 25, 2026 | February 27, 2026 |
| Insys Therapeutics, Inc.INSY · Entity 156931 | Chief Legal Officer & Gen Cnsl | January 25, 2019 | April 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Envista Holdings Corp
Report date February 25, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,252 |
Ending reported balance
After 2026-02-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-25 · Tax withholding · Disposed 3,368 · Balance 68,577 F1: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations applicable to the vesting of stock-settled Restricted Stock Units ("RSU"). Row 2 · 2026-02-25 · Grant · Acquired 12,675 · Balance 81,252 F2: Consists of RSUs that will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Each RSU will convert on a 1-for-1 basis, in shares of the Issuer's common stock. |
| Performance Share UnitSEC Table II · derivative / convertible security | Direct | 23,070 |
Reported balance
After 2026-02-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-25 · Grant · Acquired 23,070 · Balance 23,070 F3: Consists of Performance Share Units that will vest, if at all, based on certification of achievement of identified performance measures over a three-year performance period. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.59 · Expires 2036-02-25 | Direct | 30,040 |
Reported balance
After 2026-02-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-25 · Grant · Acquired 30,040 · Balance 30,040 F4: This Option will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations applicable to the vesting of stock-settled Restricted Stock Units ("RSU").
F2: Consists of RSUs that will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Each RSU will convert on a 1-for-1 basis, in shares of the Issuer's common stock.
F3: Consists of Performance Share Units that will vest, if at all, based on certification of achievement of identified performance measures over a three-year performance period. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-200% of the amount reported depending on the level of performance achieved.
F4: This Option will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date.
Insys Therapeutics, Inc.
Report date January 25, 2019 · Filed April 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,000 |
Reported balance
After 2019-01-25 transaction · row 1
1 source rowRow 1 · 2019-01-25 · Grant · Acquired 10,000 · Balance 25,000 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.81 · Expires 2029-01-24 | Direct | 70,000 |
Reported balance
After 2019-01-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-01-25 · Grant · Acquired 70,000 · Balance 70,000 F1: The option vests in 48 equal monthly installments and will be fully vested and exercisable on January 25, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 48 equal monthly installments and will be fully vested and exercisable on January 25, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2021 Filed Aug 4, 2021 17:28 UTC | Envista Holdings Corp NVST · Entity 4007 | SaleCommon Stock | 100 | $44.04 | $4,404.00 |
DisclosureSEC source: 0001757073-21-000115 · wf-form4_162811251486864.xml · nonDerivative · entry 2 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,082 F2 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 17:28 UTC | Envista Holdings Corp NVST · Entity 4007 | Exercise / conversionCommon Stock | 300 | $27.05 | $8,115.00 |
DisclosureSEC source: 0001757073-21-000115 · wf-form4_162811251486864.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This Option was originally granted by Danaher and, pursuant to the terms of the Employee Matters Agreement, was adjusted into an Option relating to shares of Issuer common stock in connection with the Separation. Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 16:59 UTC | Envista Holdings Corp NVST · Entity 4007 | Tax withholdingCommon Stock | 540 | $41.91 | $22,631.40 |
DisclosureSEC source: 0001757073-21-000110 · wf-form4_162646915521759.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,882 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations applicable to the vesting of stock-settled Restricted Stock Units ("RSU"). Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:36 UTC | Envista Holdings Corp NVST · Entity 4007 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,358 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001757073-21-000095 · wf-form4_162378936210340.xml · derivative · entry 6 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,432 Underlying: Common Stock · 8,358 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This Option will vest ratably on each anniversary of the date of grant over five years, subject to continued service through each such date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:36 UTC | Envista Holdings Corp NVST · Entity 4007 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,905 | $0.00 Strike: $27.05 | $0.00 |
DisclosureSEC source: 0001757073-21-000095 · wf-form4_162378936210340.xml · derivative · entry 5 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,622 Underlying: Common Stock · 5,905 shares Expires 2029-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Option was originally granted by Danaher and, pursuant to the terms of the Employee Matters Agreement, was adjusted into an Option relating to shares of Issuer common stock in connection with the Separation. F4 · derivative.exercise_date: This Option will vest as to 5,905 shares of Issuer common stock each of July 15, 2020, July 15, 2021, July 15, 2022 and July 15, 2023 and as to 5,907 shares of Issuer common stock on July 15, 2024, subject to continued service through each such date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:36 UTC | Envista Holdings Corp NVST · Entity 4007 | SaleCommon Stock | 8,358 | $44.05 | $368,169.90 |
DisclosureSEC source: 0001757073-21-000095 · wf-form4_162378936210340.xml · nonDerivative · entry 4 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,422 F2 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.99 to $44.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:36 UTC | Envista Holdings Corp NVST · Entity 4007 | Exercise / conversionCommon Stock | 8,358 | $26.50 | $221,487.00 |
DisclosureSEC source: 0001757073-21-000095 · wf-form4_162378936210340.xml · nonDerivative · entry 3 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:36 UTC | Envista Holdings Corp NVST · Entity 4007 | SaleCommon Stock | 5,905 | $44.05 | $260,115.25 |
DisclosureSEC source: 0001757073-21-000095 · wf-form4_162378936210340.xml · nonDerivative · entry 2 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,422 F2 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.99 to $44.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 16:36 UTC | Envista Holdings Corp NVST · Entity 4007 | Exercise / conversionCommon Stock | 5,905 | $27.05 | $159,730.25 |
DisclosureSEC source: 0001757073-21-000095 · wf-form4_162378936210340.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This Option was originally granted by Danaher and, pursuant to the terms of the Employee Matters Agreement, was adjusted into an Option relating to shares of Issuer common stock in connection with the Separation. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 16:25 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEmployee Stock Option (Right to Buy) · Derivative | 34,610 | $0.00 Strike: $37.94 | $0.00 |
DisclosureSEC source: 0001757073-21-000033 · wf-form4_161437469675657.xml · derivative · entry 3 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,610 Underlying: Common Stock · 34,610 shares Expires 2031-02-25 F4 · derivative.exercise_date: This Option will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 16:25 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 9,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001757073-21-000033 · wf-form4_161437469675657.xml · nonDerivative · entry 2 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,422 F3 · shares: Consists of RSUs that will vest ratably on each anniversary of the date of grant over three years, subject to continued service through each such date. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 16:25 UTC | Envista Holdings Corp NVST · Entity 4007 | Tax withholdingCommon Stock | 749 | $37.94 | $28,417.06 |
DisclosureSEC source: 0001757073-21-000033 · wf-form4_161437469675657.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,192 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations applicable to the vesting of stock-settled Restricted Stock Units ("RSU"). F2 · balance_after: Includes the net balance of RSUs resulting from the vesting of and related tax withholding transaction noted herein. Each RSU will convert on a 1-for-1 basis, in shares of the Issuer's common stock. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 20:07 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEnvista deferred contribution programs - Envista Stock Fund · Derivative | 967 | $35.54 Strike: $0.00 | $34,367.18 |
DisclosureSEC source: 0001757073-21-000019 · wf-form4_161361043907891.xml · derivative · entry 1 Nance Mark E · CIK 0001755882 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 967 Underlying: Common Stock · 967 shares Expires not disclosed F1 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F2 · derivative.exercise_date: Company contributions to the Excess Contribution Program ("ECP") consist of matching contributions (based on amounts the reporting person voluntary defers into the Envista Deferred Compensation Plan) and/or non-elective contributions. A participant vests in the matching contribution in the ECP made each year on the first anniversary after it is credited to the participant's account. A participant vests in the non-elective contribution in the ECP made each year on the later of the first anniversary after it is credited to the participant's account, or the date the participant has completed three years of service with Envista. F2 · derivative.expiration_date: Company contributions to the Excess Contribution Program ("ECP") consist of matching contributions (based on amounts the reporting person voluntary defers into the Envista Deferred Compensation Plan) and/or non-elective contributions. A participant vests in the matching contribution in the ECP made each year on the first anniversary after it is credited to the participant's account. A participant vests in the non-elective contribution in the ECP made each year on the later of the first anniversary after it is credited to the participant's account, or the date the participant has completed three years of service with Envista. F3 · derivative.underlying_shares: Represents the Company's annual contribution to the Envista stock fund (the "ECP Stock Fund") in the reporting person's ECP account. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Envista common stock, calculated by dividing the contribution amount by the closing price of Envista common stock as reported on the NYSE as of the first day of the year in which the contribution is made. The price shown in Table II, Column 8 is the closing price per share of Envista common stock as reported on the NYSE on the date the contribution was actually made (or the closing price for the immediately preceding business day, if such date is not a business day). F3 · balance_after: Represents the Company's annual contribution to the Envista stock fund (the "ECP Stock Fund") in the reporting person's ECP account. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Envista common stock, calculated by dividing the contribution amount by the closing price of Envista common stock as reported on the NYSE as of the first day of the year in which the contribution is made. The price shown in Table II, Column 8 is the closing price per share of Envista common stock as reported on the NYSE on the date the contribution was actually made (or the closing price for the immediately preceding business day, if such date is not a business day). F4 · balance_after: Consists of unfunded, notional shares of Envista common stock in the Envista stock fund of the reporting person's ECP account. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:39 UTC | Envista Holdings Corp NVST · Entity 4007 | Tax withholdingCommon Stock | 540 | $21.85 | $11,799.00 |
DisclosureSEC source: 0001415889-20-001920 · form4-07172020_010726.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · SENIOR VICE PRESIDENT, GC, SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,941 F1 · shares: Represents shares of the Issuer's common stock withheld to satisfy tax withholding obligations applicable to the vesting of stock-settled Restricted Stock Units ("RSU"). F2 · balance_after: Includes the net balance of RSUs resulting from the vesting of and related tax withholding transaction noted herein. Each RSU will convert on a 1-for-1 basis, in shares of the Issuer's common stock. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 20:40 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEmployee Stock Option (Right to Buy) · Derivative | 41,790 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001415889-20-000533 · form4-02262020_050239.xml · derivative · entry 2 Nance Mark E · CIK 0001755882 · SENIOR VICE PRESIDENT, GC, SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,790 Underlying: Common Stock · 41,790 shares Expires 2030-02-25 F2 · derivative.exercise_date: This Option will vest ratably on each anniversary of the date of grant over five years, subject to continued service through each such date. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 20:40 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 11,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000533 · form4-02262020_050239.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · SENIOR VICE PRESIDENT, GC, SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,481 F1 · shares: Consists of RSUs that will vest ratably on each anniversary of the date of grant over five years, subject to continued service through each such date. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:22 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantEmployee Stock Option (Right to Buy) · Derivative | 29,527 | $0.00 Strike: $27.05 | $0.00 |
DisclosureSEC source: 0000899243-19-029803 · doc4.xml · derivative · entry 2 Nance Mark E · CIK 0001755882 · Senior Vice President, GC, Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,527 Underlying: Common Stock · 29,527 shares Expires 2029-07-15 F2 · security: This Option was originally granted by Danaher and, pursuant to the terms of the Employee Matters Agreement, was adjusted into an Option relating to shares of Issuer common stock in connection with the Separation. F3 · derivative.exercise_date: This Option will vest as to 5,905 shares of Issuer common stock on each of July 15, 2020, July 15, 2021, July 15, 2022 and July 15, 2023 and as to 5,907 shares of Issuer common stock on July 15, 2024, subject to continued service through each such date. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 18:22 UTC | Envista Holdings Corp NVST · Entity 4007 | GrantCommon Stock | 9,156 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029803 · doc4.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · Senior Vice President, GC, Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,156 F1 · shares: These are restricted stock units ("RSUs") that were originally granted by Danaher Corporation ("Danaher") and, in connection with Issuer's separation from Danaher on December 18, 2019 (the "Separation") and pursuant to the terms of the Employee Matters Agreement, dated as of September 19, 2019, by and between Danaher and Issuer (the "Employee Matters Agreement"), were adjusted into RSUs relating to shares of Issuer common stock. Read SEC document |
| January 25, 2019 Filed Apr 19, 2019 21:38 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-19-025413 · doc4.xml · derivative · entry 2 Nance Mark E · CIK 0001755882 · Chief Legal Officer & Gen Cnsl 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments and will be fully vested and exercisable on January 25, 2023. Read SEC document |
| January 25, 2019 Filed Apr 19, 2019 21:38 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025413 · doc4.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · Chief Legal Officer & Gen Cnsl 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| January 25, 2019 Filed Apr 23, 2019 19:15 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-19-025632 · doc4.xml · derivative · entry 2 Nance Mark E · CIK 0001755882 · Chief Legal Officer & Gen Cnsl 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-01-24 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments and will be fully vested and exercisable on January 25, 2023. Read SEC document |
| January 25, 2019 Filed Apr 23, 2019 19:15 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025632 · doc4.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · Chief Legal Officer & Gen Cnsl 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:43 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001209191-18-054897 · doc4.xml · derivative · entry 2 Nance Mark E · CIK 0001755882 · Chief Legal Officer & Gen Cnsl 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-10-09 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments and will be fully vested and exercisable on October 10, 2022. Read SEC document |
| October 10, 2018 Filed Oct 12, 2018 16:43 UTC | Insys Therapeutics, Inc. INSY · Entity 156931 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054897 · doc4.xml · nonDerivative · entry 1 Nance Mark E · CIK 0001755882 · Chief Legal Officer & Gen Cnsl 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.